Bausch Health Companies Inc. Stock News

Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more s

Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting dat

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigat

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chron

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

The eyecare specialist did not have a banner first quarter. It posted a surprise net loss for the period.

Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participant

Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.52 per share a year ago.

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a confere

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.